RecruitingPhase 2NCT07294664

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

Clinical Study of SHR1701 in Combination With CAPOX and SHR2554 or Apatinib for First-line Treatment of Advanced Gastric Cancer

Sponsor

The First Affiliated Hospital of Zhengzhou University

Enrollment

78 participants

Start Date

Jun 15, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Gastric Cancer SHR1701

Summary

Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach. This study aims to evaluate the addition of immunomodulatory EZH2 inhibitors or anti-angiogenic agents to the baseline regimen of immunotherapy combined with chemotherapy, in order to further improve patient treatment benefits.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination of targeted therapies (a PD-1 inhibitor, a TGF-beta blocker, and an EZH2 inhibitor) together with standard chemotherapy as a first treatment for stomach or esophageal junction cancer that cannot be removed with surgery. **You may be eligible if...** - You are 18 or older - You have been diagnosed with stomach or gastroesophageal junction cancer confirmed by biopsy - You are in good physical condition (ECOG score 0-1, meaning fully active or able to do light work) - You have not previously received chemotherapy for this cancer - Your cancer is locally advanced or has spread to other parts of the body **You may NOT be eligible if...** - You have previously received chemotherapy for this condition - You have serious heart, liver, or kidney problems - You have an active autoimmune condition or infection - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.